Investor mix
9 investors on record; 1 has since exited.
| Investor type | Count | Share |
|---|---|---|
| Venture capital | 4 | 44% |
| Private equity | 3 | 33% |
| Bank & private debt | 1 | 11% |
| Other / undisclosed | 1 | 11% |
Developer of cell-based immunotherapy products for the treatment of blood cancers
9 investors on record; 1 has since exited.
| Investor type | Count | Share |
|---|---|---|
| Venture capital | 4 | 44% |
| Private equity | 3 | 33% |
| Bank & private debt | 1 | 11% |
| Other / undisclosed | 1 | 11% |